Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Chemomab Therapeutics Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement July 26, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Therapeutics Announces $10 Million Private Placement July 25, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis July 25, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis June 18, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference June 06, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Therapeutics to Participate in Upcoming Scientific Conferences May 17, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule May 08, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference May 02, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update April 24, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis April 18, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 April 02, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis March 25, 2024 From Chemomab Therapeutics Via GlobeNewswire Tickers CMMB Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.